In the list of 6 items.
Medical Fund: There is a list of technologies with a high level of innovation
Published June 30, 2023 17:33
After consulting with the Transparency Council, national consultants and the Patient Ombudsman, the Minister of Health publishes the current list of highly innovative technologies based on the list of highly innovative drug technologies prepared by the Agency for Health Technology Assessment and Tarification:
- artesunate - for the initial treatment of severe malaria in adults and children;
- tebentafusp - in monotherapy for the treatment of adult patients with human leukocyte antigen (HLA)-A*02:01 unresectable or metastatic uveal melanoma;
- Phosphenopterin - treatment of patients with molybdenum cofactor type A deficiency;
- enfortumab vedotin - monotherapy for locally advanced or metastatic urothelial carcinoma in adult patients who have received prior platinum derivative-based chemotherapy and a programmed cell death receptor 1 inhibitor or programmed cell death ligand 1 inhibitor;
- olipudase alfa - in children and adolescents and adults as enzyme replacement therapy for the treatment of symptoms of Acid Sphingomyelinase Deficiency (ASMD) type A/B or B, unrelated to the central nervous system (CNS);
- lonafarnib - treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or progeroid laminopathy with processing deficient progeroid laminopathy, which are associated with a heterozygous mutation of the LMNA gene with progerin-like protein accumulation or with a homozygous or compound heterozygous mutation of the ZMPSTE24 gene.
A detailed description of drug technologies including inclusion criteria, drug dosage, treatment monitoring and the scope of reporting and billing information is presented in the form of drug program descriptions (download).
The Minister of Health hereby informs the responsible entities whose drug technologies are on the above list of the possibility of submitting through the SOLR system the applications referred to in Article 24(1)(1b) of the Reimbursement Law.
Source: MZ
